Evidence map›Paper›PMID 41224078›Full record

ArticleMolecular & cellular proteomics : MCP2025

Quantitative Proteomics Identifies Potential Molecular Adaptations in Mouse Models of Congenital Stationary Night Blindness Type 2.

Matthias Ganglberger, Lucia Zanetti, Anna-Sophia Egger, Alexander Günter, Bettina Wagner, Soumaya Belhadj, Regine Mühlfriedel, Dagmar Knoflach, Emilio Casanova, Thomas Rülicke and 4 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthias GanglbergerInstitute of Pharmacy, Pharmacology and Toxicology Unit, University of Innsbruck, Innsbruck, Austria.
Lucia ZanettiInstitute of Pharmacy, Pharmacology and Toxicology Unit, University of Innsbruck, Innsbruck, Austria.
Anna-Sophia EggerDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, Austria.
Alexander GünterDivision of Ocular Neurodegeneration, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
Bettina WagnerDepartment of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.
Soumaya BelhadjDivision of Ocular Neurodegeneration, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
Regine MühlfriedelDivision of Ocular Neurodegeneration, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
Dagmar KnoflachInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Emilio CasanovaInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Thomas RülickeDepartment of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.
Mathias W SeeligerDivision of Ocular Neurodegeneration, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
Marcel KwiatkowskiDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, Austria.
Hartwig SeitterInstitute of Pharmacy, Pharmacology and Toxicology Unit, University of Innsbruck, Innsbruck, Austria.
Alexandra KoschakInstitute of Pharmacy, Pharmacology and Toxicology Unit, University of Innsbruck, Innsbruck, Austria. Electronic address: alexandra.koschak@uibk.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic variants in the CACNA1F gene are linked to congenital stationary night blindness type 2 though their specific molecular effects remain elusive. This study examines the retinal impact of two variants: a truncation (RX) and a gain-of-function (IT) to explore variant-specific retinal proteome changes. Electroretinography showed that RX primarily affects rod pathways, while IT disrupts both rod and cone signaling, consistent with morphological findings. Comprehensive quantitative proteomic analysis using mass spectrometry identified approximately 4000 proteins across wild-type control and mutant retinas, including also low-abundant membrane proteins. IT retinas exhibited widespread proteomic remodeling suggesting broad cellular responses and also compensatory molecular adaptations. In contrast, RX retinas displayed a more restricted profile. Similar to IT retinas, we found reduced Cav1.4 protein levels but without transcriptional downregulation in RX, alongside selective changes in synaptic proteins such as Erc1, Lrfn2, vGlut1, and Rab3a. These findings suggest selective molecular changes in synaptic organization and calcium-related pathways in RX retinas, offering insights into the mechanisms of Cav1.4 dysfunction in retinal disease. Deep proteomic analysis demonstrates how retinal cells reorganize their molecular architecture in response to calcium channel defects and highlights the utility of comprehensive proteomics to characterize adaptive cellular responses to genetic perturbations in retinal synaptic organization.

Indexed as

Eye Diseases, HereditaryGenetic Diseases, X-LinkedMyopiaNight BlindnessProteomeProteomicsAnimalsCalcium Channels, L-TypeDisease Models, AnimalElectroretinographyMiceMice, Inbred C57BLRetinaCacna1f protein, mouseCalcium Channels, L-TypeProteome

Identifiers

PMID41224078
PMCPMC12802112

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.